Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac.
Dang J, Kong V, Li W, Navarro I, Winter JD, Malkov V, Berlin A, Catton C, Padayachee J, Raman S, Warde P, Chung P. Dang J, et al. Among authors: raman s. Tech Innov Patient Support Radiat Oncol. 2022 Aug 27;23:41-46. doi: 10.1016/j.tipsro.2022.08.005. eCollection 2022 Sep. Tech Innov Patient Support Radiat Oncol. 2022. PMID: 36105770 Free PMC article.
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Among authors: raman s. Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. Eur Urol. 2021. PMID: 33685838 Clinical Trial.
Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy.
Kong VC, Dang J, Li W, Navarro I, Padayachee J, Malkov V, Winter J, Raman S, Berlin A, Catton C, Warde P, Chung P. Kong VC, et al. Among authors: raman s. Tech Innov Patient Support Radiat Oncol. 2022 Mar 2;21:64-70. doi: 10.1016/j.tipsro.2022.02.003. eCollection 2022 Mar. Tech Innov Patient Support Radiat Oncol. 2022. PMID: 35252598 Free PMC article.
Update on the systematic review/meta-analysis of uncomplicated bone metastases treated with external beam radiation.
Behroozian T, Navarro I, Hoskin P, Johnstone C, Recht A, Menten J, Oldenburger E, van der Linden Y, van der Velden JM, Nguyen QN, Simone CB 2nd, Johnstone P, Lutz S, Milton L, Andratschke N, Willmann J, Kazmierska J, Spałek M, Chow E, Raman S. Behroozian T, et al. Among authors: raman s. Radiother Oncol. 2022 Sep;174:109-110. doi: 10.1016/j.radonc.2022.07.010. Epub 2022 Jul 16. Radiother Oncol. 2022. PMID: 35850265 No abstract available.
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM, Ramotar M, Metser U, Chung PW, Liu Z, Vines D, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Among authors: raman s. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):693-704. doi: 10.1016/j.ijrobp.2022.06.080. Epub 2022 Aug 27. Int J Radiat Oncol Biol Phys. 2022. PMID: 36031465 Clinical Trial.
MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P. Ménard C, et al. Among authors: raman s. Front Oncol. 2022 Aug 26;12:971344. doi: 10.3389/fonc.2022.971344. eCollection 2022. Front Oncol. 2022. PMID: 36091157 Free PMC article.
1,708 results